help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on April 8, 2008
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2008-0304
A more recent version of this article appeared on July 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
93/7/2913    most recent
Author Manuscript (PDF)
Author Manuscript (PDF)
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gomes, L. G.
Right arrow Articles by Miller, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gomes, L. G.
Right arrow Articles by Miller, W. L.
Related Collections
Right arrow Adrenal and Hypertension

Submitted on February 7, 2008
Accepted on April 2, 2008

The Common P450 Oxidoreductase Variant A503V Is Not a Modifier Gene for 21-Hydroxylase Deficiency

Larissa G. Gomes, Ningwu Huang, Vishal Agrawal, Berenice B. Mendonça, Tania A. S. S. Bachega, and Walter L. Miller*

Department of Pediatrics, University of California San Francisco, San Francisco, CA 94143-0978 (L.G.G., N.W., V.A., W.L.M.) and Department of Endocrinology, Hospital das Clinicas da Universidade de Sao Paulo, Sao Paulo, Brazil (L.G.G., B.B.M., T.A.S.S.B.)

* To whom correspondence should be addressed. E-mail: wlmlab{at}ucsf.edu.

Context: 21-hydroxylase deficiency (21OHD) is a common genetic disorder caused by mutations in the CYP21A2 gene, which encodes the adrenal 21-hydroxylase, microsomal P450c21. CYP21A2 gene mutations generally correlate well with impaired P450c21 enzymatic activity and the clinical findings in 21OHD, but occasional discrepancies between genotype and phenotype suggest the effects of modifier genes. Mutations in P450 oxidoreductase (POR), the protein that transfers electrons from NADPH to all microsomal P450s, can ameliorate the 21OHD phenotype, and hence could be a modifier gene.

Objective: To identify POR variants in patients with 21OHD having discordant phenotype and genotype, and to evaluate their effect on 21-hydroxylase activity.

Patients and Methods: We determined the CYP21A2 genotypes of 313 Brazilian patients with 21OHD and correlated the genotype and phenotype. The POR gene was sequenced in 17 patients with discordant genotype and phenotype. Wild-type and A503V POR, and P450c21 were expressed in bacteria and reconstituted in vitro. Activities were assayed by conversion of [14C]progesterone to deoxycorticosterone and [3H]17-hydroxyprogesterone to 11-deoxycortisol, and assessed by thin layer chromatography and phosphorimaging.

Results: The A503V POR variant was found in 10/30 alleles, the same ratio as in a normal population. There were no significant differences in Km, Vmax and Vmax/Km of 21-hydroxylase activity supported by wild type and A503V POR.

Conclusion: The only POR missense polymorphism found in atypical 21OHD patients was A503V. Although A503V reduces P450c17 enzymatic activity, it does not influence P450c21 activity, indicating that POR A503V does not modify the 21OHD phenotype.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society